Curis Lifesciences SME IPO GMP Today

GMP for Curis Lifesciences SME started at Rs 0 on 31 October 2025 and stood at Rs 6 on 12 November 2025. The sharpest single-day jump was from Rs 0 on 4 Nov 2025 to Rs 6 on 5 Nov 2025. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.

Based on today's GMP, Curis Lifesciences SME IPO listing price estimate is Rs 137.00 per share (issue price Rs 128.00 + GMP Rs 9.00).

Actual listing price will be known on 14 November 2025 when the stock lists on NSE/BSE.

At about 7.0% GMP, demand looks positive but not aggressive. Listing outcome will depend heavily on subscription data and market mood on listing day.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Curis Lifesciences SME is 74.39x. Compare this with the GMP trend to see if demand aligns. The GMP move around 5 Nov 2025 may reflect how the market reacted once the subscription window activity picked up after 7 Nov 2025.

See live figures on the Curis Lifesciences SME IPO Subscription Status page.

Curis Lifesciences SME IPO full details (financials, peers, review).

Curis Lifesciences Limited is a pharmaceutical manufacturing company specializing in a wide range of dosage forms, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates through three main business models: Loan License Manufacturing (job worker for domestic clients), Contract Manufacturing (supplying finished products to domestic suppliers and merchant exporters to countries like Kenya, Nigeria, and the UK), and Direct Export / Own Brand Manufacturing (exporting products under its own brands to regions like Yemen and Kenya). The company's manufacturing facility in Sanand, Gujarat, has significant annual capacities across its various product forms and is utilizing IPO proceeds for major capacity upgrades, construction of a storage facility, and product registrations in new countries.